Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

Melanoma is a disease characterized by lesions that activate ERK. Though 70% of cutaneous melanomas harbor activating mutations in the BRAF and NRAS genes, the alterations that drive tumor progression in the remaining 30% are largely undefined. Vemurafenib, a selective inhibitor of RAF kinases, has...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nissan, Moriah H., Pratilas, Christine A., Jones, Alexis M., Ramirez, Ricardo, Won, Helen, Liu, Cailian, Tiwari, Shakuntala, Kong, Li, Hanrahan, Aphrothiti J., Yao, Zhan, Merghoub, Taha, Ribas, Antoni, Chapman, Paul B., Yaeger, Rona, Taylor, Barry S., Schultz, Nikolaus, Berger, Michael F., Rosen, Neal, Solit, David B.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4005042/
https://ncbi.nlm.nih.gov/pubmed/24576830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2625
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires